409 Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by flares, defined by US and EU guidelines as acute, clinically significant worsening of signs and symptoms of AD requiring therapeutic intervention. Flare prevention is a hallmark of long-term disease control in AD. Here, we report the effect of dupilumab treatment for 52 weeks on flare prevention in adults with moderate-to-severe AD from the LIBERTY AD CHRONOS trial (NCT02260986). In this trial, 740 patients (pts) with moderate-to-severe AD were randomized 3:1:3 to subcutaneous dupilumab 300 mg once weekly, dupilumab 300 mg every 2 weeks (q2w), or placebo (PBO); all pts also received a standardized regimen of medium potency topical corticosteroids (TCS).